HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Social Bookmarking                What's this?

Youth and Parent Satisfaction With Clinical Use of the GlucoWatch G2 Biographer in the Management of Pediatric Type 1 Diabetes

DirecNet Coordinating Center, Jaeb Center for Health Research, Tampa, Florida

Address correspondence and reprint requests to Tim Wysocki, PhD, ABPP, c/o DirecNet Coordinating Center, Jaeb Center for Health Research, 15310 Amberly Dr., Suite 350, Tampa, FL 33647. E-mail: direcnet{at}jaeb.org

OBJECTIVE—A continuous glucose monitor satisfaction scale (CGM-SAT) was evaluated during a 6-month randomized controlled trial of the GlucoWatch G2 Biographer (GW2B) in youths with type 1 diabetes.

RESEARCH DESIGN AND METHODS—At the end of the 6-month trial, 97 parents and 66 older children who had been randomized to the GW2B group completed the CGM-SAT, which assesses satisfaction on 37 items using a five-point Likert scale. Descriptive analysis, calculation of several reliability estimates, and assessment of concurrent validity were performed.

RESULTS—The CGM-SAT demonstrated high internal reliability (Cronbach’s = 0.95 for parents and 0.94 for youths aged 11 years), split-half reliability ( = 0.91 for parents and 0.93 for youths), and parent-adolescent agreement ( = 0.68, P < 0.001). Convergent validity was supported by marginally significant associations with treatment adherence and frequency of GW2B use. CGM-SAT scores did not correlate significantly with changes in treatment adherence, quality of life, or diabetes-related anxiety from baseline to 6 months. Mean scores on CGM-SAT items indicated that 81% of parental responses and 73% of youths’ responses were less favorable than "neutral." Descriptive analysis indicated the GW2B requires substantial improvement before it can achieve widespread clinical utility and acceptance.

CONCLUSIONS—The results supported the psychometric properties of the CGM-SAT. The CGM-SAT warrants further research use and cross-validation with other continuous glucose monitors. This study provides a benchmark for comparison with new glucose sensors.

Abbreviations: CGMS, continuous glucose monitoring system • CGM-SAT, continuous glucose monitor satisfaction scale • FDA, Food and Drug Administration • GW2B, GlucoWatch G2 Biographer • SMBG, self-monitoring of blood glucose

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Weinzimer, D. Xing, M. Tansey, R. Fiallo-Scharer, N. Mauras, T. Wysocki, R. Beck, W. Tamborlane, K. Ruedy, and Diabetes Research in Children Network (DirecNet) S FreeStyle Navigator Continuous Glucose Monitoring System Use in Children With Type 1 Diabetes Using Glargine-Based Multiple Daily Dose Regimens: Results of a pilot trial Diabetes Research in Children Network (DirecNet) Study Group Diabetes Care, March 1, 2008; 31(3): 525 - 527. [Full Text] [PDF]